Related Experiment Videos
Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after
1Department of Medicine and Pathology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA.
Abstract:
The incidence of recurrent type I membranoproliferative glomerulonephritis (MPGN) after renal transplant is approximately 30%, and the rate of graft loss due to recurrent MPGN type I is higher than 50%. The treatment of this disease has not been defined. We report a case of recurrent MPGN type diagnosed 4 months after a cadaveric renal transplantation. The patient was treated with cyclophosphamide and was able to maintain her graft function. Cyclophosphamide was interrupted three times during the course. Each time her renal function deteriorated and her serum albumin decreased. The patient currently has a functional renal graft 3 years after transplantation while receiving low-dose therapy with cyclophosphamide. We suggest treating recurrent type I MPGN with cyclophosphamide while continuing the calcineurin inhibitor and prednisone.
Insights
Recurrent type I membranoproliferative glomerulonephritis (MPGN) after kidney transplant often leads to graft loss. Cyclophosphamide treatment in one case stabilized graft function, suggesting its potential therapeutic role.
Area of Science:
- Nephrology
- Transplantation Immunology
- Glomerular Diseases
Background:
- Recurrent type I membranoproliferative glomerulonephritis (MPGN) affects approximately 30% of kidney transplant recipients.
- Graft loss due to recurrent MPGN type I exceeds 50%, highlighting a critical unmet clinical need.
- Established treatment protocols for recurrent MPGN type I post-transplant are lacking.
Observation:
- A case of recurrent MPGN type I was diagnosed four months post-cadaveric renal transplantation.
- The patient received cyclophosphamide treatment, which initially maintained graft function.
- Interruption of cyclophosphamide therapy correlated with renal function decline and decreased serum albumin levels.
Findings:
- Sustained low-dose cyclophosphamide therapy allowed the patient to maintain a functional renal graft for three years.
- Cyclophosphamide demonstrated a positive impact on renal function and serum albumin in the context of recurrent MPGN type I.
- The therapeutic effect of cyclophosphamide was reversible upon discontinuation, underscoring its role in disease management.
Implications:
- Cyclophosphamide may represent a viable treatment option for recurrent MPGN type I following renal transplantation.
- Combination therapy with cyclophosphamide, calcineurin inhibitors, and prednisone warrants further investigation.
- This case suggests a potential strategy to improve long-term graft survival in MPGN patients.